Japan approves Roche’s tumour agnostic cancer drug RozlytrekJapan has become the first country to approve Roche’s personalised cancer drug Rozlytrek (entrectinib). Roche added entrectinib to Share XJapan approves Roche’s tumour agnostic cancer drug Rozlytrekhttps://pharmaphorum.com/news/japan-approves-roches-tumour-agnostic-cancer-drug-rozlytrek/
Roche’s Gazyva shows promise in Lupus nephritis trialRoche’s Gazyva is already approved in leukaemia and lymphoma – but could it work in the autoimmune kidney Share XRoche’s Gazyva shows promise in Lupus nephritis trialhttps://pharmaphorum.com/news/roches-gazyva-shows-promise-in-lupus-nephritis-trial/
FDA approves Roche’s $90,000 lymphoma combinationThe FDA has quickly approved a new antibody treatment for an aggressive form of lymphoma from Roche – Share XFDA approves Roche’s $90,000 lymphoma combinationhttps://pharmaphorum.com/news/fda-approves-roches-90000-lymphoma-combination/
Roche delays Spark merger again amid reviews in US and UKRoche’s $4.3 billion takeover of US gene therapy specialist Spark Therapeutics has been pushed back again because regulators Share XRoche delays Spark merger again amid reviews in US and UKhttps://pharmaphorum.com/news/roche-delays-spark-merger-again-amid-reviews-in-us-and-uk/
Sanofi names ex-Roche cancer guru Dietmar Berger as development leadRoche alumnus Dietmar Berger has joined Sanofi as head of development following a short stint in biotech. In Share XSanofi names ex-Roche cancer guru Dietmar Berger as development leadhttps://pharmaphorum.com/news/sanofi-names-ex-roche-cancer-guru-dietmar-berger-as-development-lead/
Merck & Co’s Keytruda fails in triple negative breast cancer trialMost of the time, Merck & Co’s Keytruda (pembrolizumab) has been a consistent performer across a range of Share XMerck & Co’s Keytruda fails in triple negative breast cancer trialhttps://pharmaphorum.com/news/merck-cos-keytruda-fails-in-triple-negative-breast-cancer-trial/
Campaigners urge NHS to drop Roche acne drugCampaigners are demanding that the NHS stop prescribing Roche’s acne drug Roaccutane (isotretinoin), claiming it can lead to Share XCampaigners urge NHS to drop Roche acne drughttps://pharmaphorum.com/news/campaigners-urge-nhs-to-drop-roche-acne-drug/
Genentech signs deal with Parvus to tackle inflammatory diseasesCanada’s Parvus Therapeutics has signed a deal with Roche’s Genentech unit to develop, manufacture and market drugs for Share XGenentech signs deal with Parvus to tackle inflammatory diseaseshttps://pharmaphorum.com/news/genentech-signs-deal-with-parvus-to-tackle-inflammatory-diseases/
Roche’s entrectinib hits the mark in paediatric cancersRoche’s entrectinib for gene fusion-positive cancers has shown promising results in a range of paediatric cancers in an Share XRoche’s entrectinib hits the mark in paediatric cancershttps://pharmaphorum.com/news/roches-entrectinib-hits-the-mark-in-paediatric-cancers/
